Inovio Total Liab from 2010 to 2024

INO Stock  USD 4.19  0.18  4.49%   
Inovio Pharmaceuticals Total Liabilities yearly trend continues to be very stable with very little volatility. Total Liabilities is likely to drop to about 35.5 M. Total Liabilities is the total amount of all liabilities that Inovio Pharmaceuticals has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
1998-12-31
Previous Quarter
37.1 M
Current Value
33.5 B
Quarterly Volatility
3.3 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Latest Inovio Pharmaceuticals' Total Liab Growth Pattern

Below is the plot of the Total Liab of Inovio Pharmaceuticals over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Inovio Pharmaceuticals' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Inovio Total Liab Regression Statistics

Arithmetic Mean52,561,730
Geometric Mean34,982,073
Coefficient Of Variation77.67
Mean Deviation30,987,695
Median44,080,858
Standard Deviation40,826,692
Sample Variance1666.8T
Range137M
R-Value0.66
Mean Square Error1014.9T
R-Squared0.43
Significance0.01
Slope6,018,447
Total Sum of Squares23335.5T

Inovio Total Liab History

202435.5 M
202355.6 M
2022126.2 M
202196.3 M
202078.6 M
2019138.5 M
201844.1 M

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as Total Liab, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities55.6 M35.5 M
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.43)
Revenue Per Share
0.025
Quarterly Revenue Growth
(0.55)
Return On Assets
(0.40)
Return On Equity
(0.91)
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.